Expert Interview
Discussing CKD and the use of Akebia's Vafseo (vadadustat) for the treatment of anemia due to chronic kidney disease in adult patients on dialysis
Ticker(s): AKBAInstitution: USC
- Associate Professor of Medicine at Keck-USC School of Medicine & Medical Director of the CKD program and the Renal, Hypertension and Transplant Clinic at the LAC+USC.
- Treats patients with both HRS1 and HRS2 and over 200 patients with Anemia-CKD.
- Research focuses on advancing kidney dialysis, liver dialysis and providing a support system for the MOF/MODS multisystem failures; has been actively conducting major pharmaceutical sponsored phase II-IV clinical trials in hypertension, anemia, iron, and secondary hyperparathyroidism.
how many patients have you treated with Vafseo?
Added By: wilson_adminHow has coverage for Vafseo been?
Added By: wilson_adminOverall how useful do you think Vafseo is compared to alternatives?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
